Active Pharmaceutical Ingredients (APIs)

Active Pharmaceutical Ingredients (APIs): Manufacturing, Compliance, and Quality Insights

APIs are defined as any substance or mixture of substances used in the manufacture of a pharmaceutical product that becomes an active ingredient in the final dosage form. APIs are…

API Quality Variability Problems? Supplier, Testing, and Control Strategy Solutions

Quality variability in APIs often manifests through several observable symptoms that signal a potential problem. Early detection is crucial for preventing further complications. Common indicators include:Click to read the full…

API co-crystal / salt form inconsistency after raw material supplier change: root cause analysis (process vs lab) with CAPA effectiveness checks

Initial indications of inconsistency in co-crystal or salt form may emerge through various symptoms evident on the manufacturing floor or in the laboratory analysis. Common signs to look out for…

API packaging moisture ingress issue after raw material supplier change: risk-based approach to prevent repeat OOS across future API batches

The identification of moisture ingress typically manifests through a variety of symptoms, including:Click to read the full article.

API starting material traceability gap during stability pull at 6/12 months: how to write a defensible deviation narrative for inspections

The first step in addressing any deviation related to API starting material traceability is the identification of symptoms or signals indicative of a potential gap. Such symptoms typically include:Click to…

API container closure compatibility failure during CPV trending review: supplier qualification gaps and incoming testing upgrades to close the loop

Detection of container closure compatibility issues during CPV trending can manifest through various symptoms. It's vital to monitor these signals early in the process to mitigate potential risks. Common symptoms…

API starting material traceability gap during EU GMP inspection preparation: how to justify reprocessing vs rejection to FDA/EMA inspectors

Identifying symptoms that indicate a traceability gap is the first step in responding effectively. Some signals may include:Click to read the full article.

API microbial limit failure during routine release testing: root cause analysis (process vs lab) with CAPA effectiveness checks

Identifying the symptoms of microbial limit failures is crucial in initiating an effective investigation. Symptoms may arise from various sources, including inconsistencies in data during routine testing or unexpected results…

API heavy metals / elemental impurities OOS during FDA inspection readiness: risk-based approach to prevent repeat OOS across future API batches

Understanding the symptoms or signals indicative of an OOS result for heavy metals is the first step in any deviation investigation. Symptoms may manifest through various channels in the manufacturing…

API particle size distribution failure after re-crystallization parameter adjustment: how to justify reprocessing vs rejection to FDA/EMA inspectors

The initial signs of an API particle size distribution failure often manifest both on the production floor and within laboratory environments. Understanding these symptoms is vital for prompt investigation. Common…

API hygroscopicity-driven degradation during routine release testing: data integrity and chromatographic audit trail review steps

Understanding the symptoms associated with API hygroscopicity-driven degradation is the first step in addressing this issue. Common indicators may occur during routine release testing or within stability studies. Here are…

API nitrosamine risk exceedance during routine release testing: data integrity and chromatographic audit trail review steps

Identifying the symptoms or signals of nitrosamine risk exceedance is pivotal in initiating an effective investigation process. Common indicators may include:Click to read the full article.